ALT5 Sigma (NASDAQ:AIFC) Trading 10.5% Higher – Time to Buy?

ALT5 Sigma Corporation (NASDAQ:AIFC) rose 10.5% on Friday . The stock traded as high as $0.4201 and last traded at $0.4118. Approximately 734,001 shares traded hands during trading, a decline of 24% from the average daily volume of 969,211 shares. The stock had previously closed at $0.3727.

Wall Street Analyst Weigh In

AIFC has been the topic of a number of research reports. Weiss Ratings restated a “sell (d-)” rating on shares of ALT5 Sigma in a research note on Tuesday, July 14th. Wall Street Zen cut ALT5 Sigma from a “sell” rating to a “strong sell” rating in a research report on Saturday, April 18th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

ALT5 Sigma Trading Up 10.5%

The company has a quick ratio of 0.82, a current ratio of 0.82 and a debt-to-equity ratio of 0.03. The company’s 50 day moving average price is $0.61 and its two-hundred day moving average price is $1.11.

ALT5 Sigma (NASDAQ:AIFC) last announced its earnings results on Monday, May 18th. The company reported ($2.14) earnings per share (EPS) for the quarter. ALT5 Sigma had a negative net margin of 2,483.94% and a negative return on equity of 68.25%. The business had revenue of $4.71 million for the quarter.

Institutional Investors Weigh In On ALT5 Sigma

A number of hedge funds have recently modified their holdings of the business. Balyasny Asset Management L.P. purchased a new stake in shares of ALT5 Sigma in the 4th quarter worth $26,000. Victory Capital Management Inc. purchased a new position in ALT5 Sigma during the third quarter valued at $33,000. Captrust Financial Advisors lifted its position in ALT5 Sigma by 116.3% during the fourth quarter. Captrust Financial Advisors now owns 37,300 shares of the company’s stock valued at $41,000 after purchasing an additional 20,054 shares in the last quarter. Schonfeld Strategic Advisors LLC purchased a new position in ALT5 Sigma during the third quarter valued at $45,000. Finally, Arkadios Wealth Advisors grew its holdings in ALT5 Sigma by 80.1% during the fourth quarter. Arkadios Wealth Advisors now owns 41,620 shares of the company’s stock valued at $46,000 after purchasing an additional 18,510 shares during the period. Institutional investors own 6.27% of the company’s stock.

ALT5 Sigma Company Profile

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties.